These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 34252447)

  • 1. Determination of camostat and its metabolites in human plasma - Preservation of samples and quantification by a validated UHPLC-MS/MS method.
    Sørensen LK; Hasselstrøm JB; Gunst JD; Søgaard OS; Kjolby M
    Clin Biochem; 2021 Oct; 96():56-62. PubMed ID: 34252447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Esterase inhibitors as ester-containing drug stabilizers and their hydrolytic products: potential contributors to the matrix effects on bioanalysis by liquid chromatography/tandem mass spectrometry.
    Zheng N; Fung EN; Buzescu A; Arnold ME; Zeng J
    Rapid Commun Mass Spectrom; 2012 Jun; 26(11):1291-304. PubMed ID: 22555922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous determination of a selective adenosine 2A agonist, BMS-068645, and its acid metabolite in human plasma by liquid chromatography-tandem mass spectrometry--evaluation of the esterase inhibitor, diisopropyl fluorophosphate, in the stabilization of a labile ester-containing drug.
    Zeng J; Onthank D; Crane P; Unger S; Zheng N; Pasas-Farmer S; Arnold M
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Jun; 852(1-2):77-84. PubMed ID: 17280881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity.
    Hoffmann M; Hofmann-Winkler H; Smith JC; Krüger N; Arora P; Sørensen LK; Søgaard OS; Hasselstrøm JB; Winkler M; Hempel T; Raich L; Olsson S; Danov O; Jonigk D; Yamazoe T; Yamatsuta K; Mizuno H; Ludwig S; Noé F; Kjolby M; Braun A; Sheltzer JM; Pöhlmann S
    EBioMedicine; 2021 Mar; 65():103255. PubMed ID: 33676899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low risk of the TMPRSS2 inhibitor camostat mesylate and its metabolite GBPA to act as perpetrators of drug-drug interactions.
    Weiss J; Bajraktari-Sylejmani G; Haefeli WE
    Chem Biol Interact; 2021 Apr; 338():109428. PubMed ID: 33647240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Determination of 16 organophosphate esters in human blood by high performance liquid chromatography-tandem mass spectrometry combined with liquid-liquid extraction and solid phase extraction].
    Hou M; Shi Y; Cai Y
    Se Pu; 2021 Jan; 39(1):69-76. PubMed ID: 34227360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A validated UHPLC-MS/MS method for rapid determination of senicapoc in plasma samples.
    Sørensen LK; Petersen A; Granfeldt A; Simonsen U; Hasselstrøm JB
    J Pharm Biomed Anal; 2021 Apr; 197():113956. PubMed ID: 33626443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic fate of 14C-camostat mesylate in man, rat and dog after intravenous administration.
    Midgley I; Hood AJ; Proctor P; Chasseaud LF; Irons SR; Cheng KN; Brindley CJ; Bonn R
    Xenobiotica; 1994 Jan; 24(1):79-92. PubMed ID: 8165824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous determination of triclosan, triclocarban, triclocarban metabolites and byproducts in urine and serum by ultra-high-performance liquid chromatography/electrospray ionization tandem mass spectrometry.
    Luo Q; Zhang H; Zhou Y; Liu Z; Cai Z
    Rapid Commun Mass Spectrom; 2021 Jul; 35(14):e9117. PubMed ID: 33928686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of a carboxylesterase inhibitor of phenylmethanesulfonyl fluoride to stabilize epothilone D in rat plasma for a validated UHPLC-MS/MS assay.
    Yuan L; Fu Y; Zhang D; Xia YQ; Peng Q; Aubry AF; Arnold ME
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Oct; 969():60-8. PubMed ID: 25151331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Method development and validation for simultaneous determination of six tyrosine kinase inhibitors and two active metabolites in human plasma/serum using UPLC-MS/MS for therapeutic drug monitoring.
    Zhang M; Liu X; Chen Z; Jiang S; Wang L; Tao M; Miao L
    J Pharm Biomed Anal; 2022 Mar; 211():114562. PubMed ID: 35124453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and validation of an LC-MS/MS method for determination of hydroxychloroquine, its two metabolites, and azithromycin in EDTA-treated human plasma.
    Sok V; Marzan F; Gingrich D; Aweeka F; Huang L
    PLoS One; 2021; 16(3):e0247356. PubMed ID: 33667247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID-19.
    Kitagawa J; Arai H; Iida H; Mukai J; Furukawa K; Ohtsu S; Nakade S; Hikima T; Haranaka M; Uemura N
    Clin Transl Sci; 2021 Sep; 14(5):1967-1976. PubMed ID: 33982445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat.
    Sun G; Sui Y; Zhou Y; Ya J; Yuan C; Jiang L; Huang M
    J Virol; 2021 Sep; 95(19):e0086121. PubMed ID: 34160253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic and pancreatic metabolism and biliary excretion of the protease inhibitor camostat mesilate.
    Beckh K; Weidenbach H; Weidenbach F; Müller R; Adler G
    Int J Pancreatol; 1991; 10(3-4):197-205. PubMed ID: 1787334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous determination of curcumin diethyl disuccinate and its active metabolite curcumin in rat plasma by LC-MS/MS: Application of esterase inhibitors in the stabilization of an ester-containing prodrug.
    Ratnatilaka Na Bhuket P; Niwattisaiwong N; Limpikirati P; Khemawoot P; Towiwat P; Ongpipattanakul B; Rojsitthisak P
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Oct; 1033-1034():301-310. PubMed ID: 27595650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nirmatrelvir increases blood tacrolimus concentration in COVID-19 patients as determined by UHPLC-MS/MS method.
    Wu QG; Zeng LY; Li F; Zhu ZQ; Yin L; Meng XM; Zhang L; Zhang P; Jiang XH; Ling Y; Zhang LJ
    Eur Rev Med Pharmacol Sci; 2023 Jan; 27(2):818-825. PubMed ID: 36734723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous quantification of fosinopril and its active metabolite fosinoprilat in rat plasma by UFLC-MS/MS: Application of formic acid in the stabilization of an ester-containing drug.
    Xue K; Li G; Sun X; Hu Y; Hu L; Huang J; Si L
    J Chromatogr B Analyt Technol Biomed Life Sci; 2015 May; 990():141-9. PubMed ID: 25875586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ultra high performance liquid chromatography-time-of-flight high resolution mass spectrometry in the analysis of hexabromocyclododecane diastereomers: method development and comparative evaluation versus ultra high performance liquid chromatography coupled to Orbitrap high resolution mass spectrometry and triple quadrupole tandem mass spectrometry.
    Zacs D; Rjabova J; Pugajeva I; Nakurte I; Viksna A; Bartkevics V
    J Chromatogr A; 2014 Oct; 1366():73-83. PubMed ID: 25262032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative determination of zopiclone and zolpidem in whole blood by liquid-liquid extraction and UHPLC-MS/MS.
    Eliassen E; Kristoffersen L
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Nov; 971():72-80. PubMed ID: 25264915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.